Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece | Published in Journal of Health Economics and Outcomes Research

Loading [Contrib]/a11y/accessibility-menu.js

Metrics
Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba,

cost-effectivenesslorlatinibanaplastic lymphoma kinaseGreecenon-small cell lung cancer

• https://doi.org/10.36469/jheor.2022.32983

Pageviews and PDF downloads

Pageviews Downloads

947 all time

Last 7 days Last 30 days Last 90 days All time

Top Countries
US	243
GR	146
IN	129
GB	83
SG	34
CA	33
CN	30
RU	28
NL	24
BR	12